Iconic Labs Regulatory News (ICON)

2 April 2019

WideCells Group PLC ("WideCells" or the "Company")

Update

WideCells Group PLC, announces that, it has agreed to issue a further 5,000,000 new ordinary shares of £0.0025 each in the Company ("Ordinary Shares") to Align Research Ltd (the "Align Shares"), in relation to the settlement of outstanding fees due by the Company to Align Research Ltd.

The Company has agreed, subject only to Admission (as defined below), to issue the Align Shares and accordingly application will be made for the Align Shares to be listed on the Standard segment of the Official List of the UK Listing Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc ("Admission").

Admission is expected to take place on 4 April 2019. The Align Shares will rank pari passu in all respects with all existing Ordinary Shares.

Following Admission of the Align Shares, the Company's enlarged issued share capital will compromise 790,552,698 Ordinary Shares with voting rights. The Company does not hold any shares in treasury. The figure of 790,552,698 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

Market Abuse Regulation (MAR) Disclosure - certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

ENDS

For further information, please visit the Company's website www.widecellsgroup.com or contact: